Expertise in
40
conditions

Dr. Mei Q. Dong

Hematology Oncology | Hematology | Oncology
Legacy Salmon Creek Hospital
700 Ne 87th Ave, Suite 360, 
Vancouver, WA 
Accepting New Patients
Offers Telehealth
Expertise in
40
conditions
Legacy Salmon Creek Hospital
700 Ne 87th Ave, Suite 360, 
Vancouver, WA 

Overview

Mei Dong is a Hematologist Oncology specialist and a Hematologist practicing medicine in Vancouver, Washington.

Dr. Dong is highly rated in 40 conditions, according to our data. Her clinical expertise encompasses Familial Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, Posterior Fossa Tumor, and Pancreaticoduodenectomy.

She is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 10 clinical trials. Dr. Dong is currently accepting new patients.

Specialties

Hematology Oncology
Hematology
Oncology

Licenses

Internal Medicine in WA

Hospital Affiliations

Legacy Salmon Creek Medical Center

Languages Spoken

English
Mandarin

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser
  • EPO
  • HMO
  • POS
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Prominence Health
  • EPO
  • PPO
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 22 Less Insurance Carriers -

Locations

LEGACY SALMON CREEK HOSPITAL
700 Ne 87th Ave, Suite 360, Vancouver, WA 98664

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Avelumab, Cabozantinib S-malate
Study Phase: Phase 3
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: May 09, 2025
Intervention Type: Device, Drug
Study Drug: Cisplatin-Gemcitabine
Study Phase: Phase 2/Phase 3
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)
Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)
Enrollment Status: Terminated
Publish Date: January 29, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
Enrollment Status: Completed
Publish Date: September 27, 2017
Intervention Type: Biological, Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

14 Total Publications

Guidelines for Prevention and Management of Complications of Injection Drug Use- A WikiGuidelines Group Consensus Statement.
Guidelines for Prevention and Management of Complications of Injection Drug Use- A WikiGuidelines Group Consensus Statement.
Journal: The American journal of medicine
Published: May 30, 2026
Similar Doctors
Expertise in
5
conditions
Dr. Michael P. Recht
Hematology | Oncology
Expertise in
5
conditions
Dr. Michael P. Recht
Hematology | Oncology
Referral may be required

Doernbecher Children's Hospital

700 SW Campus Dr, 
Portland, OR 
 (10.1 miles away)
503-494-8716
Languages Spoken:
English
See accepted insurances

Michael Recht is a Hematologist and an Oncologist practicing medicine in Portland, Oregon. Dr. Recht is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Hemophilia A, Blood Clots, Hemophilia B, Glanzmann Thrombasthenia, and Endoscopy.

Expertise in
8
conditions
Dr. Hagen F. Kennecke
Hematology | Oncology
Expertise in
8
conditions
Dr. Hagen F. Kennecke
Hematology | Oncology
Referral may be required

Providence Cancer Institute Franz Clinic

4805 NE Glisan St Ste 11N-1, 
Portland, OR 
 (6.1 miles away)
503-215-5696
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hagen Kennecke is a Hematologist and an Oncologist practicing medicine in Portland, Oregon. Dr. Kennecke is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Carcinoid Syndrome. Dr. Kennecke is currently accepting new patients.

Expertise in
4
conditions
Dr. Stephen S. Roberts
Hematology | Oncology
Expertise in
4
conditions
Dr. Stephen S. Roberts
Hematology | Oncology
Referral may be required

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (10.1 miles away)
503-494-1543
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stephen Roberts is a Hematologist and an Oncologist practicing medicine in Portland, Oregon. Dr. Roberts is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Hereditary Neuroblastoma. Dr. Roberts is currently accepting new patients.

Frequently Asked Questions about Dr. Mei Q. Dong

How do I make an appointment with Dr. Mei Q. Dong?

You can book an appointment with Dr. Mei Q. Dong by calling their office at 360-896-7070. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mei Q. Dong a top-rated expert for Familial Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mei Q. Dong is classified as an Distinguished expert for Familial Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mei Q. Dong specialize in?

While Dr. Mei Q. Dong is a Hematology Oncology, they have specific expertise in Familial Colorectal Cancer, Pancreatic Cancer, and Familial Pancreatic Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Mei Q. Dong participate in research or clinical trials?

Yes. Dr. Mei Q. Dong has published 14 articles and abstracts on conditions like Familial Colorectal Cancer. You can view a list of Dr. Mei Q. Dong's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mei Q. Dong accept my insurance?

Dr. Mei Q. Dong accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 360-896-7070 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dong's expertise for a condition
ConditionClose
    View All 37 Advanced Conditions
    View All 128 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile